Sihuan Pharmaceutical Wins Approval in China for Botox Injection

Sihuan Pharmaceutical has won approval from China’s National Medical Products Administration for an injectable Type A botulinum toxin product, Letybo 100U.

The product will be manufactured by South Korea-based biopharmaceutical company Hugel and Sihuan says it plans to start selling the drug in China by year’s end.

The Chinese market for injectable botox products is expected to increase from just $600 million last year to $1.8 billion by 2025, making it the world’s third-largest market after the U.S. and the European Union.